Genitourinary Cancers Clinical Trials & Research at Providence Medical Group
Providence Medical Group is currently enrolling patients for the following
genitourinary cancers clinical trials:
Urothelial Cancer
Prostate Cancer
Renal Cell Cancer
Study to Assess the Effect of PF_06946860 on Appetite Following Subcutaneous
Administration to Patients with Anorexia and Advanced Cancer
Treatment agent: PF-06946860
PI: Sara Keck, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707)
521-3833 ext. 1313
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04803305?term=PF-06946860&draw=2&rank=2
Sponsor: Pfizer
Urothelial
A Study of Enfortumab Vedotin Alone or with Other Therapies for Treatment
of Urothelial Cancer (EV-103)
Treatment: Enfortumab Vedotin
PI:
Ian Anderson, MD
Study Coordinator: Teresa Lund //
Teresa.Lund@stjoe.org // (707) 521-3803 ext. 1103
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT03288545
Prostate
A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus
Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant
Prostate Cancer Associated with Homologous Recombination Deficiency (TRITON3)
Treatment agent: Rucaparib (PARPi)
PI:
Wes Lee, MD
Study Coordinator: Teresa Lund //
Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links:
clinicaltrials.gov NCT No: NCT02975934
Renal Cell